Related Experiment Video

Updated: May 7, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition

Jesse D Riordan, Teagan A Nathanson, Afshin Varzavand

    Biorxiv : the Preprint Server for Biology
    |January 7, 2025
    PubMed

    Insights

    The Rac1 P29S mutation causes resistance to melanoma treatments by activating alternative pathways. Combining RAF/MEK inhibitors with FAK inhibitors shows promise for treating this aggressive form of skin cancer.

    Area of Science:

    • Oncology
    • Dermatology
    • Molecular Biology

    Background:

    • The Rac1 P29S mutation in cutaneous melanoma confers resistance to MAPK pathway inhibitors (MAPKi).
    • Activation of Rac1 guanine exchange factors (GEFs) also drives MAPKi-resistance, especially in undifferentiated melanoma cells.
    • Understanding Rac1-driven resistance mechanisms is crucial for developing effective therapeutic strategies.

    Purpose of the Study:

    • To delineate the mechanisms of Rac1-driven MAPKi-resistance in cutaneous melanoma.
    • To identify novel therapeutic strategies to inhibit the growth of Rac1-driven melanomas.
    • To evaluate the efficacy of combined RAF/MEK and FAK inhibition.

    Main Methods:

    • Investigated pleiotropic resistance mechanisms including reduced BRAF/MEK dependence, activation of Jun kinase and p38 MAP kinase pathways, and YAP/TAZ signaling.
    • Assessed the dependency on focal adhesion kinase (FAK) signaling in Rac1-driven melanoma cells.
    • Evaluated the combination of auvotometinib (RAF/MEK clamp) and defactinib (FAK inhibitor).

    Main Results:

    • Rac1-driven melanomas exhibit reduced but not complete ERK independence.
    • Activated Rac1 creates a dependency on FAK signaling in undifferentiated melanoma cells.
    • Combined inhibition of RAF/MEK with auvotometinib and FAK with defactinib suppressed Rac1-driven melanoma cell growth.

    Conclusions:

    • Combined auvotometinib and defactinib is a promising strategy for Rac1-driven MAPKi-resistant melanoma.
    • This combination may be effective in heavily pre-treated, advanced cutaneous melanoma.
    • The combination is currently being investigated for brain metastatic cutaneous melanoma.

    More Related Videos

    Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

    Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

    Published on: July 17, 2019

    5.9K
    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

    Published on: October 5, 2020

    2.9K

    Related Concept Videos

    MAPK Signaling Cascades01:07

    MAPK Signaling Cascades

    Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
    4.9K
    Interactions Between Signaling Pathways01:19

    Interactions Between Signaling Pathways

    Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
    Convergence and divergence, and cross-talk between signaling pathways
    Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
    6.1K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.6K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    3.2K
    Intracellular Signaling Affects Focal Adhesions01:17

    Intracellular Signaling Affects Focal Adhesions

    Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
    Some...
    2.5K
    Small GTPases - Ras and Rho01:24

    Small GTPases - Ras and Rho

    Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
    Three regulatory proteins control their activity:
    3.8K